Vestipitant

Vestipitant
IUPAC ime
(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
Identifikatori
CAS broj334476-64-1 ДаY
ATC kodnone
PubChemCID 9832383
Hemijski podaci
FormulaC23H21F10N3O
Molarna masa545.416 g/mol
  • FC(F)(F)c1cc(F)ccc1C2CNCCN2C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(c3)C(F)(F)F

Vestipitant je razvio GlaksoSmitKlajn. Ovaj lek deluje kao selektivni antagonist za NK1 receptor. On je u razvoju kao potencijalni antiemetik i anksiolitik[1][2], i kao lek za tinitus.[3]

Reference

[уреди | уреди извор]
  1. ^ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). „Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis”. Supportive cancer therapy. 3 (3): 140—2. PMID 18632487. doi:10.3816/SCT.2006.n.011. 
  2. ^ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR; Olivier, B (2008). „Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents”. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 18 (10): 729—50. PMID 18657401. doi:10.1016/j.euroneuro.2008.06.002. 
  3. ^ Clinical Trials NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss

Vidi još

[уреди | уреди извор]

Spoljašnje veze

[уреди | уреди извор]



Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).